Carbocyclic Sulfone RORγ Modulators for Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents fail to adequately address the unmet medical need in treating inflammatory and autoimmune diseases, particularly those involving dysregulated IL-17 production, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and asthma, where RORγt plays a critical role.
Innovation Solution
Development of compounds that modulate RORγt activity, specifically antagonizing it to treat diseases by administering therapeutically effective amounts of compounds of formula (I) or their pharmaceutical compositions, which include stereoisomers, pharmaceutically acceptable salts, and solvates, to target inflammatory and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to treat inflammatory and autoimmune diseases, then treatment is provided, but adequate therapeutic benefit is not achieved due to dysregulated IL-17 production
Solution Approach 1:
The patent extracts and targets the specific harmful function of RORγt in IL-17 production by developing selective modulators that isolate and inhibit this particular receptor pathway, separating it from other immune functions. This allows treatment of IL-17 driven diseases while preserving other immune responses.
Solution Approach 2:
The patent modifies the pharmacological parameters of RORγt interaction by developing compounds with specific binding affinities and functional selectivity. The modulators change the activation state of RORγt from pro-inflammatory to non-active, altering the biological output without completely blocking the receptor.
2Object-generated harmful factors
If RORγt is inhibited to reduce IL-17 production, then disease symptoms are ameliorated, but off-target effects and safety concerns arise
Solution Approach 1:
The patent applies local quality by creating modulators with specific binding characteristics that target only the RORγt receptor in a localized manner. The compounds exhibit selective affinity for RORγt over other related receptors (RORα, RORβ), ensuring that inhibition is confined to the intended target and does not broadly affect other immune pathways.
Solution Approach 2:
The patent introduces intermediary compounds that mediate the interaction between immune system components and disease pathology. These modulators act as selective intermediaries that block the harmful RORγt-IL-17 axis while allowing other immune communications to proceed normally, thus reducing off-target effects.
3Adaptability or versatility
If existing therapeutic agents are administered, then treatment is provided, but unmet medical need remains in treating diverse inflammatory and autoimmune conditions
Solution Approach 1:
The patent achieves universality by developing a modular approach to RORγt modulation that can be applied across multiple disease states. The same receptor-targeting strategy works for psoriasis, rheumatoid arthritis, IBD, and other IL-17 driven conditions, providing a universal therapeutic platform that adapts to different disease contexts through dose and formulation adjustments.
Data Source
AI summary
Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.